advanced search

<< Back To Home

Background Documents and Presentations, SAGE meeting of October 2016

Tuesday, 25th of October 2016

Background Documents and Presentations, SAGE meeting of October 2016

Centre International de Conference Genève (CICG) - Salle 2 in Geneva, 18-20 October 2016

Background documents

For weblinks to background documents, go to

http://www.who.int/immunization/sage/meetings/2016/october/presentations_background_docs/en/

 

For weblinks to presentations, go to http://www.who.int/immunization/sage/meetings/2016/october/presentations_background_docs/en/index1.html

 

• SAGE Yellow Book - October 2016 
  pdf, 18.70Mb
• Meeting of the Strategic Advisory Group of Experts on immunization, April 2016 – conclusions and recommendations
  pdf, 493kb
• SAGE tracking record of recommendations and action points
  pdf, 515kb
• Immunization highlights 2015
  pdf, 459kb
• Report of the AFRO Regional Immunization Technical Advisory Group Meeting, 5-8 July 2016, Brazzaville, Congo.
  pdf, 926kb
• Ministerial conference on immunization in Africa
  pdf, 3.64Mb
• Ad-hoc Virtual TAG Meeting 2016- XXIV Meeting of the Technical Advisory Group on Vaccine-preventable Diseases, 13 May 2016, Washington, DC, USA.
  pdf, 442kb
• Immunization highlights 2015, Report of the WHO Regional Office for Europe
  pdf, 3.47Mb
• How to respond to vocal vaccine deniers in public. Best practice guidance, EURO
  pdf, 1.12Mb
• Seventh Meeting of the South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG): Full report
  pdf, 349kb
• 25th Meeting of the Technical Advisory Group on Immunization and Vaccine Preventable Diseases, 26-29 July 2016, Manila, Philippines: Full report
  pdf, 1.38Mb
• Update on the 22-23 June 2016 Gavi Board Meeting
  pdf, 60kb
• Review of decisions, Gavi Alliance Board Meeting, 22-23 June 2016, Geneva 
  pdf, 251kb
• Minutes of the Gavi Alliance Board Meeting, 22-23 June 2016, Geneva
  pdf, 369kb
• Global Advisory Committee on Vaccine Safety (GACVS), 15-16 June 2016. WER 2016;91:341-348
  pdf, 304kb
• Summary of GACVS reviews of HPV vaccines 
  pdf, 661kb
• Report from the World Health Organization´s Third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016
  pdf, 600kb
• Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC) summary of conclusions and recommendations, 30 May-1 June 2016 meeting. WER 2016;91:389-96
  pdf, 317kb

Session: Report from IVB director

Session: Report from GAVI, the Vaccine Alliance

Session: Report from other advisory committees on immunization

Session: Report of activities from international immunization partners

There are no background documents for this session.

Session: Global polio eradication initiative

• SAGE Polio WG - notes from August 2016 meeting 
  pdf, 248kb
• Fractional-dose inactivated poliovirus vaccination campaign, Telangana state, India, June 2016. WER 2016; 91:397–404
  pdf, 474kb
• Update on Vaccine-Derived Polioviruses — Worldwide, January 2015–May 2016. MMWR August 5, 2016 / 65(30);763–769
  pdf, 220kb
• Cessation of Use of Trivalent Oral Polio Vaccine and Introduction of Inactivated Poliovirus Vaccine — Worldwide, 2016. MMWR (to be published) or WER version WER 2016;91:421-427
  pdf, 6.24Mb
• 13th Independent Monitoring Board Report
• GAPIII Containment Certification Scheme 
  pdf, 536kb
  This document is intended to replace the two pages of Annex 4 of GAPIII: WHO verification that certified poliovirus-essential facilities comply with GAPIII.
• Measles and Rubella Global Strategic Plan 2012-2020 Midterm Review
  pdf, 1.96Mb
• WHO Policy Recommendation on Measles Second Dose (MCV2): Considerations for removing the criteria for introduction
  pdf, 1.09Mb
• Measles and Rubella: Regional Progress Updates
  pdf, 8.01Mb
• Measles vaccines: WHO position paper. WER 2009;84:349-60
  pdf, 369kb
• Rubella vaccines: WHO position paper. WER 2011;86:301-16
  pdf, 414kb
• Report of the SAGE Working Group on Maternal and Neonatal Tetanus Elimination and Broader Tetanus Prevention
  pdf, 1.06Mb
• Evidence to recommendation tables and GRADE tables
  pdf, 210kb
• Tetanus vaccine WHO position paper
  pdf, 193kb
• Community-based strategies including tetanus vaccination for preventing neonatal and/or maternal tetanus: Review of published reviews
  pdf, 512kb
• Vaccination schedules used for preventing neonatal and/or maternal tetanus and duration of vaccine-induced protection: Review of published reviews
  pdf, 472kb
• Compilation of presentations delivered to SAGE WG on MNTE and broader tetanus prevention
  pdf, 16.30Mb
• Draft 2016 Mid Term Review of the Global Vaccine Action Plan 
  pdf, 421kb
• 2016 GVAP secretariat report 
  pdf, 14.14Mb
• Regional vaccine action plans 2016 progress reports
  pdf, 11.41Mb
• GVAP 2016 reports from seven priority countries
  pdf, 3.34Mb
• 2016 immunization score cards
  pdf, 6.85Mb
• Background summary, conclusions and recommendations on Hepatitis B containing vaccines
  pdf, 4.56Mb
• Global burden of HBV-attributable liver cancer
  pdf, 562kb
• Systematic review of safety and efficacy of childhood schedules using of hepatitis B containing vaccines
  pdf, 7.96Mb
• Update of the review on seroprotection after recombinant hepatitis B vaccination among newborn infants
  pdf, 600kb
• Literature review of the thermostability of hepatitis B containing vaccines
  pdf, 1.25Mb
• Review of the barriers to implement the birth dose of hepatitis B
  pdf, 824kb
• Hepatitis B: an updated systematic review of economic evaluations in low and middle income countries
  pdf, 558kb
• Background paper: Schedules and strategies for human papillomavirus (HPV) immunization
  pdf, 1.45Mb
• Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Global Health 2016; 4: e609–16
  pdf, 480kb
• Anogenital warts: Incidence, prevalence, self-reported history & quality of life. Cochrane; September 2016
  pdf, 3.84Mb
• Randomized controlled trials of human papillomavirus vaccines: Systematic reviews prepared by Cochrane Response, London, UK; September 2016
  pdf, 6.59Mb
• Summary of evidence: Population-level impact and herd effects following papillomavirus immunization programmes: a systematic review and meta-analysis; CHU de Québec – Université Laval
  pdf, 419kb
• Summary of evidence: Human Papilloma Virus (HPV) Vaccination: An updated systematic review of cost-effectiveness analyses. Monash University Malaysia
  pdf, 636kb
• Modelling estimates of the incremental effectiveness & cost-effectiveness of HPV vaccination
  pdf, 256kb
• Summary of GACVS reviews of HPV vaccines 
  pdf, 661kb
• Executive summary: Session on yellow fever vaccines
  pdf, 78kb
• Global strategy to eliminate yellow fever epidemics (EYE)
  pdf, 4.50Mb
• Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response. WHO secretariat information paper, 20 July 2016
  pdf, 1.26Mb
• Yellow fever mass vaccination campaign using fractional dose in Kinshasa
  pdf, 134kb
• Short-term research priorities for dose-sparing of YF vaccine (Revised version 26 September 2016)
  pdf, 98kb
• 6. Vaccines and vaccination against yellow fever. WHO position paper – June 2013. WER 203;88:269-84
  pdf, 1.20Mb

Session: Measles and rubella elimination

Session: Maternal and neonatal tetanus elimination and overall tetanus prevention

Session: Global Vaccine Action Plan

Session: Hepatitis B vaccination

Session: HPV vaccines

Session: Yellow fever

 

 

Presentations

Session: Report from IVB director

• Global report including key updates and challenges from regions.
  pdf, 6.11Mb
  J.-M. Okwo-Bele
• Report from Gavi, the Vaccine Alliance.
  pdf, 1.19Mb
  A. Nguyen
• Report of the Global Advisory Committee on Vaccine Safety (GACVS)
  pdf, 1.74Mb
  R. Pless
• Product Development for Vaccines Advisory Committee (PDVAC)
  pdf, 845kb
  D. Kaslow
• Report of the Immunization and vaccines related implementation research advisory committee (IVIR-AC)
  pdf, 1.16Mb
  R. Breiman
• Bill and Melinda Gates Foundation (BMGF)
  pdf, 1.72Mb
  O. Levin
• World Bank
  pdf, 5.68Mb
  T. Palu
• Objective of the session and overview of Global Polio Eradication Initiative
  pdf, 4.41Mb
  M. Zaffran
• Updates on implementation of OPV2 withdrawal
  pdf, 1.77Mb
  D. Chang-Blanc
• Report from SAGE Polio WG
  pdf, 2.17Mb
  Y. AL-Mazrou
• Global measles and rubella update
  pdf, 1.74Mb
  P. Strebel
• Findings and recommendations of the Mid Term Review of the measles and rubella strategic plan 2012-2020
  pdf, 566kb
  W. Orenstein
• Measles second dose introduction criteria
  pdf, 2.75Mb
  N. Turner
• Update on the current MNTE strategy, achievements, successes and challenges including country experiences
  pdf, 2.79Mb
  A. Raza
• Broader tetanus prevention: Impact of current tetanus immunization programmes and need for acquiring broader tetanus prevention
  pdf, 800kb
  R. Steinglass
• Review of key conclusions and recommendations by the SAGE Working Group
  pdf, 1.57Mb
  K. Johansen
• The GVAP Secretariat Report 2016: Update on process, new indicators, actions taken by the secretariat in response to previous reports
  pdf, 1.26Mb
  T. Cherian
• Summary of GVAP implementation progress review and recommendations for corrective actions at the mid-term of the Decade of Vaccines
  pdf, 2.12Mb
  A. Cravioto
• Introduction and key questions for the session
  pdf, 476kb
  K. Johansen
• Hepatitis B infection -related disease burden, Immunogenicity and safety of hepatitis B vaccine schedules and thermostability of hepatitis B vaccines
  pdf, 2.90Mb
  F. de la Hoz Restrepo
• Observed and forecasted impact of different hepatitis B immunization schedules and strategies
  pdf, 1.39Mb
  J. Edmunds
• Conclusions and proposed recommendations for SAGE
  pdf, 267kb
  K. Johansen
• Introduction and key questions for the session
  pdf, 345kb
  A. Pollard
• Update on HPV vaccine introduction and programmatic perspective
  pdf, 4.79Mb
  I. Ogbuanu
• HPV-related disease burden and effects of different HPV immunization schedules and strategies
  pdf, 3.58Mb
  M. Ramsay
• Observed and forecast impact of different HPV immunization schedules and strategies
  pdf, 1.48Mb
  M. Brisson
• Conclusions and proposed recommendations for SAGE
  pdf, 4.48Mb
  A. Pollard

Session: GAVI

Session: Reports from other Advisory Committees on Immunization

Session: Report of activities from international immunization partners

Session: Polio eradication initiative

Session: Measles and rubella elimination

Session: Maternal and neonatal tetanus elimination and overall tetanus prevention

Session: Global Vaccine Action Plan (GVAP)

Session: Hepatitis B vaccination

Session: HPV vaccines

Session: Yellow fever

Part 1: Long term Yellow Fever strategy

• Epidemiology and risk of yellow fever in current context
  pdf, 2.22Mb
  O. Tomori
• Yellow fever vaccine supply: Projected availability and opportunities for scaling up
  pdf, 538kb
  A. Costa
• Global Strategy for Eliminating Yellow fever Epidemics (EYE)
  pdf, 1.06Mb
  O. Ronveaux

Part 2: Options for emergency surge capacity

• Introduction and context to surge capacity needs
  pdf, 1.02Mb
  J. Hombach
• Fractional dosing of Yellow fever vaccines: review of vaccine potency & stability information, available evidence, and evidence gaps
  pdf, 614kb
  A. Barrett
• Feedback from the DRC Yellow fever fractional dose campaign
  pdf, 1.87Mb
  R. Mihigo
• Secretariat recommendations and key research needs
  pdf, 815kb
  J. Hombach